Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020

Guangdong province, located in South China, is an important economic hub with a large domestic migrant population and was among the earliest areas to report COVID-19 cases outside of Wuhan. We conducted a cross-sectional, age-stratified serosurvey to determine the seroprevalence of antibodies agains...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cheng Xiao, Nancy Hiu Lan Leung, Yating Cheng, Hui Lei, Shiman Ling, Xia Lin, Ran Tao, Xianzhong Huang, Wenda Guan, Zifeng Yang, Benjamin John Cowling, Mark Zanin, Sook-San Wong
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	SARS-CoV-2 coronavirus disease 2019 seroprevalence Guangdong China antibody Medicine R
Acceso en línea:	https://doaj.org/article/e3e39062a27c42e1bd5dd0ddb05526ab
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e3e39062a27c42e1bd5dd0ddb05526ab
record_format	dspace
spelling	oai:doaj.org-article:e3e39062a27c42e1bd5dd0ddb05526ab2021-11-25T18:38:47ZSeroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 202010.3390/pathogens101115052076-0817https://doaj.org/article/e3e39062a27c42e1bd5dd0ddb05526ab2021-11-01T00:00:00Zhttps://www.mdpi.com/2076-0817/10/11/1505https://doaj.org/toc/2076-0817Guangdong province, located in South China, is an important economic hub with a large domestic migrant population and was among the earliest areas to report COVID-19 cases outside of Wuhan. We conducted a cross-sectional, age-stratified serosurvey to determine the seroprevalence of antibodies against SARS-CoV-2 after the emergence of COVID-19 in Guangdong. We tested 14,629 residual serum samples that were submitted for clinical testing from 21 prefectures between March and June 2020 for SARS-CoV-2 antibodies using a magnetic particle based chemiluminescent enzyme immunoassay and validated the results using a pseudovirus neutralization assay. We found 21 samples positive for SARS-CoV-2 IgG, resulting in an estimated age- and sex-weighted seroprevalence of 0.15% (95% CI: 0.06–0.24%). The overall age-specific seroprevalence was 0.07% (95% CI: 0.01–0.24%) in persons up to 9 years old, 0.22% (95% CI: 0.03–0.79%) in persons aged 10–19, 0.16% (95% CI: 0.07–0.33%) in persons aged 20–39, 0.13% (95% CI: 0.03–0.33%) in persons aged 40–59 and 0.18% (95% CI: 0.07–0.40%) in persons ≥60 years old. Fourteen (67%) samples had pseudovirus neutralization titers to S-protein, suggesting most of the IgG-positive samples were true-positives. Seroprevalence of antibodies to SARS-CoV-2 was low, indicating that there were no hidden epidemics during this period. Vaccination is urgently needed to increase population immunity to SARS-CoV-2.Cheng XiaoNancy Hiu Lan LeungYating ChengHui LeiShiman LingXia LinRan TaoXianzhong HuangWenda GuanZifeng YangBenjamin John CowlingMark ZaninSook-San WongMDPI AGarticleSARS-CoV-2coronavirus disease 2019seroprevalenceGuangdongChinaantibodyMedicineRENPathogens, Vol 10, Iss 1505, p 1505 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	SARS-CoV-2 coronavirus disease 2019 seroprevalence Guangdong China antibody Medicine R
spellingShingle	SARS-CoV-2 coronavirus disease 2019 seroprevalence Guangdong China antibody Medicine R Cheng Xiao Nancy Hiu Lan Leung Yating Cheng Hui Lei Shiman Ling Xia Lin Ran Tao Xianzhong Huang Wenda Guan Zifeng Yang Benjamin John Cowling Mark Zanin Sook-San Wong Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020
description	Guangdong province, located in South China, is an important economic hub with a large domestic migrant population and was among the earliest areas to report COVID-19 cases outside of Wuhan. We conducted a cross-sectional, age-stratified serosurvey to determine the seroprevalence of antibodies against SARS-CoV-2 after the emergence of COVID-19 in Guangdong. We tested 14,629 residual serum samples that were submitted for clinical testing from 21 prefectures between March and June 2020 for SARS-CoV-2 antibodies using a magnetic particle based chemiluminescent enzyme immunoassay and validated the results using a pseudovirus neutralization assay. We found 21 samples positive for SARS-CoV-2 IgG, resulting in an estimated age- and sex-weighted seroprevalence of 0.15% (95% CI: 0.06–0.24%). The overall age-specific seroprevalence was 0.07% (95% CI: 0.01–0.24%) in persons up to 9 years old, 0.22% (95% CI: 0.03–0.79%) in persons aged 10–19, 0.16% (95% CI: 0.07–0.33%) in persons aged 20–39, 0.13% (95% CI: 0.03–0.33%) in persons aged 40–59 and 0.18% (95% CI: 0.07–0.40%) in persons ≥60 years old. Fourteen (67%) samples had pseudovirus neutralization titers to S-protein, suggesting most of the IgG-positive samples were true-positives. Seroprevalence of antibodies to SARS-CoV-2 was low, indicating that there were no hidden epidemics during this period. Vaccination is urgently needed to increase population immunity to SARS-CoV-2.
format	article
author	Cheng Xiao Nancy Hiu Lan Leung Yating Cheng Hui Lei Shiman Ling Xia Lin Ran Tao Xianzhong Huang Wenda Guan Zifeng Yang Benjamin John Cowling Mark Zanin Sook-San Wong
author_facet	Cheng Xiao Nancy Hiu Lan Leung Yating Cheng Hui Lei Shiman Ling Xia Lin Ran Tao Xianzhong Huang Wenda Guan Zifeng Yang Benjamin John Cowling Mark Zanin Sook-San Wong
author_sort	Cheng Xiao
title	Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020
title_short	Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020
title_full	Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020
title_fullStr	Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020
title_full_unstemmed	Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020
title_sort	seroprevalence of antibodies to sars-cov-2 in guangdong province, china between march to june 2020
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/e3e39062a27c42e1bd5dd0ddb05526ab
work_keys_str_mv	AT chengxiao seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020 AT nancyhiulanleung seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020 AT yatingcheng seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020 AT huilei seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020 AT shimanling seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020 AT xialin seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020 AT rantao seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020 AT xianzhonghuang seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020 AT wendaguan seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020 AT zifengyang seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020 AT benjaminjohncowling seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020 AT markzanin seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020 AT sooksanwong seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020
_version_	1718410868370178048

Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020

Ejemplares similares